Abi-Saab Walid 4

What Happened

• Walid Abi‑Saab, Chief Medical Officer of uniQure (QURE), received two grants of restricted share units (RSUs) on March 4, 2026: 41,700 RSUs (reported as an acquisition) and 67,200 RSUs (reported as a derivative acquisition), for a total of 108,900 RSUs. These were granted at $0.00 (no cash purchase).
• On the same date he disposed of 808 ordinary shares in an open-market sale at a weighted average price of $9.06, generating approximately $7,320. The sale was executed automatically to cover estimated withholding taxes upon RSU vesting.

Key Details

• Transaction date(s): March 4, 2026; Form 4 filed March 6, 2026.
• Sale price: weighted average $9.06 per share (range $9.00–$9.22). Proceeds ≈ $7,320.
• Grants: 41,700 RSUs (A) and 67,200 RSUs (A, derivative). Reported acquisition price $0.00.
• Ownership after transaction: not disclosed in the filing.
• Notable footnotes:
  • F1: RSUs granted under the 2014 Share Incentive Plan; each RSU converts to one ordinary share and vests in three equal annual installments beginning one year after grant.
  • F2: The 808-share sale was an automatic sell-to-cover for tax withholding, not a discretionary trade by the reporting person.
  • F3: Sale price is a weighted average; multiple executions between $9.00 and $9.22.
  • F4: (Describes a stock option vesting schedule included in the filing; not an exercised-option transaction here.)
• Filing timeliness: Form 4 was filed two days after the transactions; filing date consistent with usual reporting (no late-filing flag indicated).

Context

• RSU grants are compensation awards that vest over time and are not an outright purchase; they represent a contingent right to shares subject to continued service.
• The small sale was routine sell-to-cover tax withholding tied to vesting and should not be interpreted as a discretionary bearish signal.